Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, USA.
Health Serv Res. 2012 Dec;47(6):2097-117. doi: 10.1111/j.1475-6773.2012.01462.x. Epub 2012 Sep 21.
To evaluate the comparative cost-effectiveness of interventions to improve adherence to evidence-based medications among postmyocardial infarction (MI) patients.
DATA SOURCES/STUDY SETTING: Cost-effectiveness analysis.
We developed a Markov model simulating a hypothetical cohort of 65-year-old post-MI patients who were prescribed secondary prevention medications. We evaluated mailed education, disease management, polypill use, and combinations of these interventions. The analysis was performed from a societal perspective over a lifetime horizon. The main outcome was an incremental cost-effectiveness ratio (ICER) as measured by cost per quality-adjusted life year (QALY) gained.
DATA COLLECTION/EXTRACTION METHODS: Model inputs were extracted from published literature.
Compared with usual care, only mailed education had both improved health outcomes and reduced spending. Mailed education plus disease management, disease management, polypill use, polypill use plus mailed education, and polypill use plus disease management cost were $74,600, $69,200, $133,000, $113,000, and $142,900 per QALY gained, respectively. In an incremental analysis, only mailed education had an ICER of less than $100,000 per QALY and was therefore the optimal strategy. Polypill use, particularly when combined with mailed education, could be cost effective, and potentially cost saving if its price decreased to less than $100 per month.
Mailed education and a polypill, once available, may be the cost-saving strategies for improving post-MI medication adherence.
评估改善心肌梗死后(MI)患者依从性的干预措施的比较成本效益。
数据来源/研究范围:成本效益分析。
我们开发了一个马尔可夫模型,模拟了一组假定的 65 岁 MI 后患者的队列,这些患者被开了二级预防药物。我们评估了邮寄教育、疾病管理、多药联合治疗以及这些干预措施的组合。分析从全社会角度在终生范围内进行。主要结果是增量成本效益比(ICER),以每获得质量调整生命年(QALY)的成本来衡量。
数据收集/提取方法:模型输入从已发表的文献中提取。
与常规护理相比,只有邮寄教育在改善健康结果的同时还降低了成本。邮寄教育加疾病管理、疾病管理、多药联合治疗、邮寄教育加多药联合治疗和疾病管理加多药联合治疗的成本分别为每获得一个 QALY 增加 74600 美元、69200 美元、133000 美元、113000 美元和 142900 美元。在增量分析中,只有邮寄教育的 ICER 低于 100000 美元/ QALY,因此是最佳策略。多药联合治疗,特别是与邮寄教育联合使用时,如果价格降至每月 100 美元以下,可能具有成本效益,并且具有潜在的成本节约效果。
邮寄教育和多药联合治疗,一旦可用,可能是改善 MI 后药物依从性的节省成本策略。